Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial

Jackson, G.H., Pawlyn, C., Cairns, D.A. et al. (20 more authors) (2021) Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial. PLOS Medicine, 18 (1). e1003454. ISSN 1549-1277

Abstract

Metadata

Authors/Creators:
  • Jackson, G.H.
  • Pawlyn, C.
  • Cairns, D.A.
  • de Tute, R.M.
  • Hockaday, A.
  • Collett, C.
  • Jones, J.R.
  • Kishore, B.
  • Garg, M.
  • Williams, C.D.
  • Karunanithi, K.
  • Lindsay, J.
  • Rocci, A.
  • Snowden, J.A. ORCID logo https://orcid.org/0000-0001-6819-3476
  • Jenner, M.W.
  • Cook, G.
  • Russell, N.H.
  • Drayson, M.T.
  • Gregory, W.M.
  • Kaiser, M.F.
  • Owen, R.G.
  • Davies, F.E.
  • Morgan, G.J.
Copyright, Publisher and Additional Information: © 2021 Jackson et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Dates:
  • Accepted: 23 November 2020
  • Published (online): 11 January 2021
  • Published: 11 January 2021
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Sheffield Teaching Hospitals
Depositing User: Symplectic Sheffield
Date Deposited: 23 Mar 2021 13:31
Last Modified: 23 Mar 2021 13:31
Status: Published
Publisher: Public Library of Science (PLoS)
Refereed: Yes
Identification Number: https://doi.org/10.1371/journal.pmed.1003454
Related URLs:

Share / Export

Statistics